sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

Douglas Ingram

sarepta.com/ →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Netcapital Reports Third Quarter Fiscal 2026 Financial Results and Provides Corporate Update

Shareholders who lost money in Shares of Camping World Holdings, Inc. (NYSE: CWH) Should Contact Wolf Haldenstein Immediately

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EOSE

LANXESS Aktiengesellschaft (LNXSY) Q4 2025 Press Conference Call Transcript

Freight Technologies Releases Pro Forma Financial Statements for JAK Solar Acquisition

Euromax Announces Closing of Issuance of Securities to EBRD in Connection with Partial Repayment of Debt

Trump Gold Coin Moves Forward

Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline

Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation (ORCL); April 6, 2026, Lead Plaintiff Deadline

National Bank Holdings Corporation Reports Granting of Inducement Awards Under NYSE Listing Rule 303A.08

FCPT Announces Acquisition of a Panera Bread Property for $3.8 Million

Barksdale Announces Closing of Crescat Private Placement

Nvidia to sell 1 million chips to Amazon by end of 2027 in cloud deal

Is Hess Midstream's Capital Return Program a Strength or a Warning Sign?

Why Signet Jewelers Stock Jumped Today

Delivra Health Brands Launches Dream Water(R) Kids Sleep Gummies in the United States Market

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Should You Forget Nvidia and Buy These 2 Artificial Intelligence (AI) Stocks Instead?

Odysight.ai Reports Full Year 2025 Financial Results and Strategic Progress Across Aerospace, Defense, and Industrial Markets

Live Nation CEO Grilled Over Ticket Fees at Antitrust Trial

About